UniProt Q5S007 · PDB · AlphaFold · Substrate: LRRKtide · Clone: aa 970-2527high-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Ceritinib | 99.4% | 0.6% | 95.44 | 0.618 |
| 2 | Gilteritinib | 97.2% | 2.8% | 88.97 | 0.506 |
| 3 | Brigatinib | 96.6% | 3.4% | 82.96 | 0.513 |
| 4 | Sunitinib | 95.8% | 4.2% | 91.73 | 0.524 |
| 5 | Defactinib | 95.8% | 4.2% | 92.68 | 0.450 |
| 6 | Alectinib | 94.5% | 5.5% | 95.49 | 0.651 |
| 7 | Midostaurin | 93.0% | 7.0% | 78.64 | 0.500 |
| 8 | Axitinib | 92.3% | 7.7% | 93.23 | 0.688 |
| 9 | Pacritinib | 83.4% | 16.6% | 88.64 | 0.452 |
| 10 | Osimertinib | 82.4% | 17.6% | 97.24 | 0.733 |
| 11 | Abemaciclib | 79.1% | 20.9% | 91.48 | 0.563 |
| 12 | Upadacitinib | 73.3% | 26.7% | 97.98 | 0.663 |
| 13 | Bosutinib | 69.5% | 30.5% | 87.22 | 0.555 |
| 14 | Fostamatinib | 69.3% | 30.6% | 96.74 | 0.613 |
| 15 | Repotrectinib | 68.8% | 31.2% | 84.21 | 0.608 |
| 16 | Nintedanib | 67.2% | 32.8% | 90.23 | 0.608 |
| 17 | Ponatinib | 63.4% | 36.6% | 78.23 | 0.534 |
| 18 | Ruxolitinib | 63.0% | 37.0% | 98.25 | 0.592 |
| 19 | Baricitinib | 62.8% | 37.2% | 97.99 | 0.616 |
| 20 | Abrocitinib | 62.1% | 37.9% | 99.50 | 0.581 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 1.02
- Epithelial log2(TPM+1): 0.44
- Fold change: 0.58
- Status: No significant change
High-confidence drugs
- Ceritinib — inh 99.4% · KISS 46.18
- Alectinib — inh 94.5% · KISS 36.61
- Axitinib — inh 92.3% · KISS 34.79
Selectivity landscape vs inhibition on LRRK2
Each point is one of the 92 approved drugs; color = inhibition % on LRRK2.
Mutation lollipop
Cancer-associated mutations plotted by residue position. Marker size + color scale with the number of distinct cancer reports.
Variants (3)
Mutation × cancer associations
| Mutation | Cancer | Organ | Source |
|---|---|---|---|
| G2019S | carcinoma_large_intestine | Large Intestine | ref |
| R1441C | carcinoma_endometrium | Uterus | ref |
| R1441C | UCEC-US | Uterus | ref |
| R1441C | UCEC | Uterus | ref |
| I2020T | carcinoma_breast | Breast | ref |
| I2020T | AML-US | Blood/Lymphatic System | ref |
| I2020T | UCEC | Uterus | ref |
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…